GlassScriptPhysician profile
Dimosthenis Mantopoulos
NPI 1679816326
$4,688.20
in general payments reported to CMS, 2019-2025
11 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $750 · 2022: $915 · 2023: $1,427 · 2024: $512 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,390 · Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,390.00 |
| Food and Beverage | $1,081.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,206.54 | 2020-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $1,411.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $522.85 | 2022-2025 | Eylea Hd |
| Astellas Pharma US INC | $260.18 | 2024-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $70.09 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Abbvie INC. | $53.04 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $48.17 | 2025 | Xipere |
| Johnson & Johnson Surgical Vision, INC. | $43.14 | 2022 | |
| Sandoz INC. | $30.01 | 2024 | Cimerli |
| Genentech USA, INC. | $22.94 | 2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $19.98 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimosthenis Mantopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.